These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29091198)

  • 21. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients.
    Chow WZ; Lim SH; Ong LY; Yong YK; Takebe Y; Kamarulzaman A; Tee KK
    PLoS One; 2015; 10(9):e0137281. PubMed ID: 26335136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
    Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
    Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
    Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
    Hughes RA; Sterne JA; Walsh J; Bansi L; Gilson R; Orkin C; Hill T; Ainsworth J; Anderson J; Gompels M; Dunn D; Johnson MA; Phillips AN; Pillay D; Leen C; Easterbrook P; Gazzard B; Fisher M; Sabin CA
    HIV Med; 2011 Nov; 12(10):583-93. PubMed ID: 21569188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
    Wood E; Hogg RS; Yip B; Tyndall MW; Sherlock CH; Harrigan RP; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):159-66. PubMed ID: 12045678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.
    Hoffmann CJ; Schomaker M; Fox MP; Mutevedzi P; Giddy J; Prozesky H; Wood R; Garone DB; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):34-41. PubMed ID: 23344547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration.
    Drylewicz J; Eholie S; Maiga M; Zannou DM; Sow PS; Ekouevi DK; Peterson K; Bissagnene E; Dabis F; Thiébaut R;
    AIDS; 2010 Apr; 24(7):1043-50. PubMed ID: 20397306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
    Gezie LD
    BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.
    Ndumbi P; Falutz J; Pant Pai N; Tsoukas CM
    PLoS One; 2014; 9(4):e94018. PubMed ID: 24710051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High level of virological suppression among HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa, Ethiopia.
    Mekuria LA; Nieuwkerk PT; Yalew AW; Sprangers MA; Prins JM
    Antivir Ther; 2016; 21(5):385-96. PubMed ID: 26731316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
    Cardoso SW; Luz PM; Velasque L; Torres TS; Tavares IC; Ribeiro SR; Moreira RI; Veloso VG; Moore RD; Grinsztejn B
    BMC Infect Dis; 2014 Dec; 14():699. PubMed ID: 25523385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
    Joly V; Fagard C; Grondin C; Descamps D; Yazdanpanah Y; Charpentier C; Colin de Verdiere N; Tabuteau S; Raffi F; Cabie A; Chene G; Yeni P;
    Antimicrob Agents Chemother; 2013 Feb; 57(2):758-65. PubMed ID: 23165467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.
    Martin DA; Luz PM; Lake JE; Clark JL; Veloso VG; Moreira RI; Cardoso SW; Klausner JD; Grinsztejn B
    BMC Infect Dis; 2014 Jun; 14():322. PubMed ID: 24919778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
    Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
    Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.